Women with multiple sclerosis who are planning a pregnancy and face a high risk of disease reactivation require a carefully structured pre-conception approach. This protocol addresses that specific clinical scenario.
This protocol applies to female patients with multiple sclerosis who are actively planning pregnancy and are assessed as being at high risk of disease reactivation. Persistent high disease activity is not currently present. The central challenge is protecting against relapse during the pre-conception period while accounting for the safety requirements of pregnancy itself.
A specific category of disease-modifying therapy is recommended during the pre-conception period for women in this risk group. In certain carefully selected cases, continuing treatment beyond conception may also be a consideration — the full protocol defines the criteria and the step-by-step management path.
Full regimen details, sequencing, and eligibility criteria are available in the complete protocol below.DOI: 10.1177/1352458517751049
For women planning a pregnancy, if there is a high risk of disease reactivation, consider using interferon or glatiramer acetate until pregnancy is confirmed.
In some very specific (active) cases, continuing this treatment during pregnancy could also be considered.
Advise all women of childbearing potential that DMDs are not licensed during pregnancy, except glatiramer acetate 20 mg/mL.
View source ↗